Welcome to our dedicated page for Cerence SEC filings (Ticker: CRNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cerence Inc. (NASDAQ: CRNC) SEC filings page brings together the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. As a software company focused on conversational AI for automotive and transportation, Cerence uses its SEC filings to report material events, financial results, restructuring actions, and significant agreements.
Investors can use this page to access 8-K filings that announce quarterly and annual financial results, as well as presentations used on earnings calls. These filings often include discussions of revenue from software licenses and cloud-connected services, key performance indicators such as the percentage of worldwide auto production with Cerence technology, and commentary on the company’s AI platforms and product adoption. Other 8-Ks describe material events such as restructuring plans related to certain foreign operations, retention and equity award arrangements for senior executives, and notable transactions.
Cerence has also filed 8-Ks detailing the resolution of patent disputes and the execution of a cross-license agreement with Samsung, which resulted in a one-time lump sum payment, and disclosing the announcement of financial results for specific periods. These documents provide insight into the company’s intellectual property strategy and its approach to monetizing and protecting its technology.
On Stock Titan, SEC filings for CRNC are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy disclosures, highlight key sections in annual and quarterly reports, and surface important items such as restructuring charges, executive compensation arrangements, and material agreements. Users interested in Cerence’s regulatory history, financial condition, and corporate actions can review 10-Ks, 10-Qs, 8-Ks, and other forms here, and use AI summaries to quickly understand the implications of each filing.
Cerence Inc. (CRNC) filed a current report to announce that it has released its financial results for the fiscal year ended September 30, 2025. The company distributed a detailed press release, attached as Exhibit 99.1, and an earnings release investor presentation, attached as Exhibit 99.2, to discuss its full-year performance. Both exhibits include non-GAAP financial measures along with explanations of these metrics and reconciliations to GAAP figures, giving investors additional ways to review the company’s results. The materials are furnished under Item 2.02 of the report and are not treated as filed for liability purposes.
Cerence Inc. announced a resolution of its patent disputes with Samsung through a cross‑license agreement. As part of the settlement, Samsung agreed to pay Cerence a one‑time lump sum of $49,500,000.
The agreement resolves two cases: “Samsung I,” filed October 13, 2023, and “Samsung II,” filed March 15, 2024. Samsung had asserted counterclaims in July 2024, and trials had been scheduled for October 2025 and April 2026. The cross‑license, reached on October 28, 2025, concludes the litigation path and provides Cerence with a defined cash inflow in place of uncertain trial outcomes.
Brian M. Krzanich, a Director and the Chief Executive Officer of Cerence Inc. (CRNC), reported a disposition of 132,075 shares of common stock on 10/09/2025 at a reported sale price of $11.4585 per share. After the reported transaction, the reporting person beneficially owned 905,987 shares. The filing explains the sale represented a mandatory "sell to cover" to satisfy tax withholding for vested restricted stock units and was not a discretionary trade by the reporting person. The Form 4 was signed on 10/10/2025 by an attorney-in-fact.
Jennifer Salinas, EVP Chief Admin Officer of Cerence Inc. (CRNC), reported two sales of company common stock. On 10/06/2025 she sold 64,784 shares at $12.7573 to satisfy tax withholding required by the company’s RSU sell-to-cover policy. The following day, on 10/07/2025, she sold 77,994 shares at $12.3122 under a pre-established Rule 10b5-1 trading plan adopted on 02/11/2025. After the transactions her reported direct beneficial ownership is 346,289 shares. The filings include a signature dated 10/07/2025 and state the sales were procedural (tax withholding and an existing trading plan) rather than discretionary trades.
Cerence Inc. (CRNC) insider transactions show routine equity activity by CFO Antonio Rodriquez. On 08/15/2025 he purchased 1,795 shares through the companys Employee Stock Purchase Plan at $10.06, bringing his holding to 315,078 shares. On 10/06/2025 he sold 38,347 shares at $12.7573, reducing the stake to 276,731 shares; the sale is identified as a mandatory "sell-to-cover" to satisfy tax-withholding for vested RSUs and not a discretionary trade. The Form 4 is filed jointly by one reporting person and is signed by an attorney-in-fact.
Cerence Inc. (CRNC) reported an insider transaction by EVP and Chief Revenue Officer Christian Mentz showing a mandatory sale of 26,872 shares on 10/06/2025 at a reported price of $12.7573 per share to satisfy tax-withholding on vested restricted stock units (RSUs). After the transaction the reporting person beneficially owned 111,875 shares, reported as disposed for Form 4 purposes. The Form 4 clarifies this was a company‑mandated "sell to cover" to cover tax obligations and is described as not a discretionary trade by the reporting person. The filing was signed by an attorney-in-fact on 10/07/2025.
Cerence Inc. (CRNC) reported a non‑discretionary sale by EVP Product & Technology Nils Schanz on 10/06/2025. The filing shows 30,560 shares were sold at a price of $12.7573 per share to satisfy tax withholding for vested restricted stock units; the company elected a "sell‑to‑cover" method. After the transaction, the reporting person beneficially owns 204,981 shares. The filing is a routine Section 16 disclosure documenting an issuer‑mandated tax withholding sale rather than a voluntary trade.
Cerence Inc. (CRNC) reported a Form 144 notice showing a proposed sale of 77,994 common shares valued at $960,269.93, with an approximate sale date of 10/07/2025 on NASDAQ. The filing shows those shares were acquired as restricted stock from the issuer on 10/01/2025 and paid for on that date. The filing also discloses a recent sale by Jennifer Salinas of 64,784 common shares on 10/06/2025 for gross proceeds of $826,468.92. The notice includes the required attestation that the seller does not possess undisclosed material adverse information and follows Rule 144 procedures for proposed insider sales.
Cerence Inc. (CRNC) reported an insider grant on a Form 4 showing 90,252 restricted stock units granted to Nils Schanz, Executive Vice President, Product & Technology, on 10/01/2025. The units were issued at a nominal price of $0.01 per share and increased his beneficial ownership to 235,541 shares following the grant. The RSUs vest in three equal installments with one-third vesting on each of 10/01/2026, 10/01/2027, and 10/01/2028. The filing is signed by an attorney-in-fact on 10/03/2025.
Cerence Inc. is launching a restructuring plan focused on certain foreign operations to cut costs and aim for profitable growth. The company expects cash restructuring charges of about $7.2 to $7.9 million, mainly for severance, notice payments, benefits and related costs. Most of these expenses are expected in the first quarter of fiscal 2026, with implementation largely complete by the end of that quarter, although local legal requirements could extend some position eliminations.
On the same date, Cerence approved a retention package for its Executive Vice President of Product and Technology, Nils Schanz. He will receive a cash retention bonus of $350,000, repayable in full if he resigns or is terminated for cause on or before August 25, 2026. He is also granted a one-time equity award with a target value of $2,000,000, split between time-based and performance-based restricted stock units that vest over three years, tied in part to performance metrics for fiscal years 2026, 2027 and 2028.